PepGen Inc. said Monday it expects its initial public offering of 7.8 million shares to price between $13 and $15 a share in a bid to raise about $109 million, based on the midpoint of its price range. The Cambridge, Mass., developer of medicine to treat Duchenne muscular dystrophy plans to trade on the Nasdaq under the symbol "PEPG" with underwriters BofA Securities, SVB Securities, Stifel and Wedbush PacGrow. Principal shareholders of PepGen include Viking Global Partners LLC, entities affiliated with RA Capital and Oxford Science Enterprises plc.